Capricor Therapeutics to Present Exosome Platform Updates
1 day ago · Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare ...
Capricor Therapeutics to Present Exosome Platform Updates at …
1 day ago · Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Oct 9, 2024 · Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor seeks FDA approval of deramiocel for Duchenne based …
5 days ago · I highly recommend Adam Feuerstein’s piece over at STAT News on this new Capricor data including insights related to the FDA and the agency’s decision on Sarepta. From the piece: “In the short term, deramiocel can preserve cardiac function,” said Marbán. “From a long-term perspective, we are hoping and anticipating to see a mortality ...
Capricor Therapeutics Announces Initiation of Rolling Submission …
SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
Capricor stock rallies 20% on DMD data presentation update
Oct 4, 2024 · Capricor Therapeutics (NASDAQ: CAPR) stock rallied 20% Friday afternoon following news the company plans to present long-term data from its HOPE-2 open-label extension study of its lead drug...
Capricor Therapeutics to Present Exosome Platform Updates at …
1 day ago · -Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the ...
Capricor Therapeutics to Present Third Quarter 2024 ... - BioSpace
Nov 5, 2024 · Company to Host Conference Call, November 13, 2024 at 4:30 p.m. ET. SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday ...
Capricor Therapeutics to Present Third Quarter 2024 Financial …
Nov 5, 2024 · Company to Host Conference Call, November 13, 2024 at 4:30 p.m. ET. SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday ...
Capricor Therapeutics, Inc. (CAPR) Latest Stock News
Get the latest Capricor Therapeutics, Inc. (CAPR) stock news and headlines to help you in your trading and investing decisions.